文献速递心境障碍

KCNQ(Kv7)通道开放剂依佐加滨对重性抑郁障碍纹状体脑奖赏区域静息态功能连接、抑郁及快感缺失的影响:一项随机对照试验结果

Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial.
PubMed 文献 · Biol Psychiatry · 2025-03-04

该双盲随机安慰剂对照试验纳入18至65岁重性抑郁障碍患者,比较依佐加滨(n=19)与安慰剂(n=21)每日给药5周的效果。依佐加滨较安慰剂显著降低奖赏种子区与后扣带皮层/楔前叶的静息态功能连接,且该降低与抑郁严重度减轻相关;快感缺失(SHAPS)和抑郁症状(MADRS)的改善也与奖赏种子区与中/后扣带区域连接降低相关。作者认为依佐加滨的抗抑郁效应可能通过调节纹状体-中/后扣带连接介导。

要点

  • 依佐加滨较安慰剂显著降低奖赏种子区与后扣带皮层/楔前叶的静息态功能连接
  • 该连接降低与抑郁严重度减轻相关
  • 快感缺失和抑郁症状改善与奖赏种子区与中/后扣带区域连接降低相关

核心结论

  • 作者认为依佐加滨的抗抑郁效应可能通过调节纹状体-中/后扣带连接介导,提示KCNQ靶向药物对重性抑郁障碍和快感缺失的潜在治疗机制。
  • 作者指出未来研究应在更大规模试验中验证这些结果。

研究设计与样本

  • 双盲、随机、安慰剂对照临床试验,纳入18至65岁重性抑郁障碍个体,比较依佐加滨每日给药(n=19)与安慰剂(n=21)共5周。
  • 采用功能磁共振成像评估基线及治疗后脑关键奖赏区域(腹侧尾状核、伏隔核)的静息态功能连接。
  • 采用Snaith-Hamilton快感量表(SHAPS)、蒙哥马利-阿斯伯格抑郁评定量表(MADRS)及其他临床症状量表测量临床症状。

主要发现

  • 依佐加滨较安慰剂显著降低奖赏种子区与后扣带皮层(PCC)/楔前叶之间的静息态功能连接,该降低与抑郁严重度减轻相关。
  • 依佐加滨较安慰剂在快感缺失(SHAPS)和抑郁症状(MADRS)上的改善与奖赏种子区与中/后扣带区域(中扣带皮层、PCC、楔前叶)连接降低相关。

局限性

  • 作者指出未来研究应在更大规模试验中验证这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major depressive disorder (MDD) is a leading cause of disability worldwide, with available treatments often showing limited efficacy. Recent research suggests that targeting specific subtypes of depression and understanding the underlying brain mechanisms can improve treatment outcomes. This study investigates the potential of the potassium KCNQ (Kv7) channel opener ezogabine to modulate the resting-state functional connectivity (RSFC) of the brain's reward circuitry and alleviate depressive symptoms, including anhedonia, a core feature of MDD. METHODS: A double-blind, randomized, placebo-controlled clinical trial in individuals with MDD ages 18 to 65 years compared daily dosing with ezogabine (n= 19) with placebo (n = 21) for 5 weeks. Functional magnetic resonance imaging assessed RSFC of the brain's key reward regions (ventral caudate, nucleus accumbens) at baseline and posttreatment. Clinical symptoms were measured using the Snaith-Hamilton Pleasure Scale (SHAPS), Montgomery-Åsberg Depression Rating Scale (MADRS), and other clinical symptom scales. RESULTS: Ezogabine significantly reduced RSFC between the reward seeds and the posterior cingulate cortex (PCC)/precuneus compared with placebo, which was associated with a reduction in depression severity. Improvements in anhedonia (SHAPS) and depressive symptoms (MADRS) with ezogabine compared with placebo were also associated with decreased connectivity between the reward seeds and mid/posterior cingulate regions (midcingulate cortex, PCC, precuneus). CONCLUSIONS: The findings suggest that ezogabine's antidepressant effects are mediated through modulation of striatal-mid/posterior cingulate connectivity, indicating a potential therapeutic mechanism for KCNQ-targeted drugs for MDD and anhedonia. Future studies should validate these results in larger trials.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Chowdhury A, Boukezzi S, Costi S, et al. Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial. Biol Psychiatry. 2025. PMID: 40049579. doi:10.1016/j.biopsych.2025.02.897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。